172 related articles for article (PubMed ID: 34733662)
21. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
Xie H; Yao J; Wang Y; Ni B
Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
[TBL] [Abstract][Full Text] [Related]
22. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
[TBL] [Abstract][Full Text] [Related]
23. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
24. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2.
Wang T; Ge G; Ding Y; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Chin Med J (Engl); 2014; 127(12):2357-62. PubMed ID: 24931256
[TBL] [Abstract][Full Text] [Related]
25. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
26. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells.
Zhang F; Wang Q; Ye L; Feng Y; Zhang X
J Med Virol; 2010 May; 82(6):920-8. PubMed ID: 20419804
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.
Li S; Yang J; Wang J; Gao W; Ding Y; Ding Y; Jia Z
Cell Biosci; 2018; 8():9. PubMed ID: 29445446
[TBL] [Abstract][Full Text] [Related]
30. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.
Redova M; Poprach A; Besse A; Iliev R; Nekvindova J; Lakomy R; Radova L; Svoboda M; Dolezel J; Vyzula R; Slaby O
Tumour Biol; 2013 Feb; 34(1):481-91. PubMed ID: 23150176
[TBL] [Abstract][Full Text] [Related]
31. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
32. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
33. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
Zhou X; Jin W; Jia H; Yan J; Zhang G
J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
[TBL] [Abstract][Full Text] [Related]
34. Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9.
Kou X; Ding H; Li L; Chao H
Anal Cell Pathol (Amst); 2021; 2021():6662486. PubMed ID: 33680718
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene.
Sun X; Lou L; Zhong K; Wan L
Exp Biol Med (Maywood); 2017 Jun; 242(12):1299-1305. PubMed ID: 28429654
[TBL] [Abstract][Full Text] [Related]
36. miRNA-181a-5p Enhances the Sensitivity of Cells to Cisplatin in Esophageal Adenocarcinoma by Targeting CBLB.
Yang S; Wang P; Wang S; Cong A; Zhang Q; Shen W; Li X; Zhang W; Han G
Cancer Manag Res; 2020; 12():4981-4990. PubMed ID: 32612385
[TBL] [Abstract][Full Text] [Related]
37. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.
Kim EA; Kim SW; Nam J; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
Oncotarget; 2016 May; 7(22):31832-46. PubMed ID: 27092874
[TBL] [Abstract][Full Text] [Related]
39. Capn4 induces human renal cancer cell proliferation by activating NF-κB signaling pathway through FAK phosphorylation.
Shen J; Zhuang Q; Chen Z; Fan M; Lu H; Ding T; He X
Int J Clin Exp Pathol; 2017; 10(7):7466-7474. PubMed ID: 31966590
[TBL] [Abstract][Full Text] [Related]
40. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
